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A clinician’s guide for navigating the world
of attention deficit hyperactivity disorder
medications
Gregory W. Mattingly1* and Joel L. Young2
1

Midwest Research Group, Washington University School of Medicine, St. Louis, Missouri, USA, and 2Rochester Center
for Behavioral Medicine, Rochester Hills, Michigan, USA

Once considered a condition of hyperactive boys, our knowledge and understanding of attention
deficit hyperactivity disorder (ADHD) and has dramatically evolved.1 Landmark studies by
Biederman, Kessler, Faraone, and others have changed and deepened our understanding of
ADHD to include a condition which not only affects boys but quite often affects girls.1–5 The
evolution of symptoms across the lifespan and the concomitant neurologic changes which
underlie this symptomatic expression has similarly evolved.6 Studies by Dalsgaard and others
have brought to light the significantly increased morbidity and mortality associated with preschoolers, children, and adults struggling with ADHD and associated conditions.7,8
This article will help clinicians:
(1) Develop a deeper understanding of the evolution of ADHD symptoms and functional
struggles across the age span.
(2) Become familiar with rating scales that evaluate ADHD symptoms, behavioral challenges,
and functional difficulties in ADHD.
(3) Learn how to optimize outcomes and manage breakthrough symptoms.
(4) Understand the onset, offset, and duration of action of various ADHD medications.
(5) Develop strategies to adjust or combine medications to address breakthrough symptoms in
the morning, afternoon, or evening.

Consequences of ADHD Across the Lifespan

© The Author(s), 2021. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.

ADHD is a common neurodevelopmental disorder affecting approximately 8% to 11% of schoolaged children, both in the United States and throughout the rest of the developed world.9 ADHD
has come to be recognized as a condition which affects both boys and girls and often persists from
childhood to adolescence and into adulthood.10 The classic triad of hyperactivity, impulsivity,
and inattention captures many of the core aspects of ADHD but fails to capture some of the
difficulties surrounding executive function and emotional reactivity which collectively account
for much of the social, educational, occupational, and emotional impairment of the disorder. In
early childhood and throughout grade school ADHD is diagnosed more frequently in boys than
girls; possibly relating to the higher expression of overt hyperactive symptomatology which is
found in preadolescent boys.5 ADHD patients with predominantly inattentive symptoms are
often overlooked, misdiagnosed, or diagnosed 2 to 3 years later in life in that the overt outward
marker of hyperactivity has often been used to identify this condition.
Our basic understanding of the neurophysiology of ADHD has advanced dramatically with
studies by investigators such as Nora Volkow, who highlighted the differences in dopamine
transporter activity in children with ADHD, Philip Shaw who tracked maturation of the prefrontal
cortex in children with ADHD, and studies looking at the influence of genetic heritability and
environmental factors.2,11 These studies, taken in total, show that ADHD is a highly genetic
neurologic condition which affects numerous cortical and subcortical pathways that coordinate
information processing, impulsivity, emotional modulation, and neurochemical pathways that
modulate communication between these cortical regions. ADHD has an overall genetic heritability
of approximately 75%, that is, three out of four times there will be a genetic family history. There is
also an important impact of environmental factors and the influence of the environment upon our
genes with epigenetic changes occurring in a number of our children exposed to environmental
stressors such as prenatal nicotine exposure, lead exposure, or severe psychosocial trauma.12,13
Long-term follow-up longitudinal studies have shown that ADHD children are at greater risk
of academic difficulties, emotional dysregulation with oppositional defiant disorder tendencies
and emotional volatility. Longitudinal imaging studies have shown a 2 to 3 year delay in
maturation of the prefrontal cortex and associated pathways in children with ADHD as
compared to non-ADHD controls.6 It is therefore not surprising that ADHD symptomatology
continues to evolve throughout childhood, adolescence, and into early adulthood as the underlying neurophysiology of the brain continues to mature and is influenced by outside environmental demands such as high school, college, employment, and the social demands of adulthood.
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By adolescence, there is an increased rate of drug and alcohol
abuse, an increased rate of motor vehicle and traffic-related difficulties and a dramatically increased rate of teenage pregnancy for
ADHD individuals compared to controls.9 Followed on into adulthood, ADHD individuals have lower occupational and economic
performance, have increased difficulty with financial management,
have increased rates of psychiatric comorbidity such as depression,
alcohol, and drug abuse, intermittent explosive disorder, and a
variety of anxiety disorders.14 ADHD adults have increased rates
of marital dysfunction and divorce, dramatically worsened abilities
to maintain ongoing friendships and significantly lower evaluations of self-esteem and self-worth.15
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or ≥6 inattentive and six hyperactive/impulsive symptoms to meet
criteria for a combined presentation. Longitudinal studies of
ADHD children followed into adulthood by Barkley found that
ADHD adults had difficulty remembering symptoms dating back
to early childhood and therefore the DSM V diagnostic criteria
have been modified.14 For a diagnosis in late adolescence or adulthood, several symptoms must have been present before age 12 and
there must continue to be ≥5 of nine symptoms in either the
inattentive, hyperactive/impulsive, or in both domains for
diagnosis.

Improving the Accuracy of ADHD Diagnosis and Treatment
Can Treatment Make a Difference?
Although classic ADHD studies have shown that both behavioral
and medical interventions can improve core ADHD symptoms,
there has been debate about the overall long-term functional
impact of ADHD interventions. Studies by Biederman, Wilens,
and others have shown that consistent ADHD treatment decreased
the rate of drug and alcohol abuse later in life.15 Numerous studies
in analog classroom settings have shown improved performance on
task-related activities such as completing math problems and
improvement on behavioral tasks measured by rating scales such
as the SKAMP (Swanson, Kotkin, Atkins, M-Flynn, and Pelham).16
Studies by Dalsgaard and others have shown that ADHD is
associated with significantly increased morbidity and mortality.7,8
These studies have found increased rates of accidental injury
requiring medical treatment and injury requiring emergency room
intervention. Utilizing the Danish birth registry, Dalsgaard found
that on a nationwide basis ADHD individual had dramatically
increased mortality rates compared to the general population.
ADHD preschoolers had an 86% increased mortality rate,
school-aged students had a 58% increased mortality rate, and
adults with ADHD had a 325% increased mortality rate relative
to non-ADHD individuals within the same population.5 These
studies went on to analyze whether ADHD treatment within the
overall population of Denmark impacted these adverse outcomes.
They found that ADHD treatment was associated with an overall
decrease in accidental injury and medical utilization due to accidents and trauma. On a nationwide basis, they found a 25% to 37%
decrease in emergency room utilization among ADHD individuals
receiving treatment versus those not receiving treatment.7
Similarly, a 2 year follow-up study of ADHD adults in the
United States found that women had a 27% reduction and men
had 34% reduction in motor vehicle trauma rates in the months
where they took their medications as compared to the months
where they were unmedicated. Treatment was even more impactful
in those with high impulsivity with men who ride motorcycles
having a 49% reduction in trauma rates in the months where they
took their medications.17

Diagnosis and Recognition of Symptoms
ADHD is a pervasive condition with symptoms that start in childhood or adolescence and involve a core of 18 classic symptoms.10
According to DSM V criteria, children with ADHD must have a
persistent pattern of inattention and/or hyperactivity-impulsivity
that interferes with functioning with ≥6 of nine inattentive symptoms for an inattentive presentation, ≥ 6 of nine hyperactive/
impulsive symptoms for a hyperactive/impulsive presentation

Clinical data and research evidence have highlighted the need to
shift from a subjective to a more objective measure of ADHD
diagnosis and treatment. A variety of fairly sensitive and specific
ADHD rating scales have been developed to better define and
measure ADHD symptoms both during initial diagnosis and
throughout ongoing treatment. While in no way substituting for
a thorough clinical evaluation, these scales help to:
(1) Better quantify and define ADHD impairments during the
initial diagnosis.
(2) Measure ADHD symptoms at various time points throughout
the day.
(3) Track ADHD symptoms to make sure that overall symptomatic improvement, symptomatic remission, and functional
normalization have been optimized for each patient.
(4) Save time by providing an objective measure of symptom
severity before meeting with a patient.

Why Should a Clinician Use ADHD Rating Scales?
Just as it is helpful for an internist to know an individual’s blood
pressure or hemoglobin A1c when diagnosing and optimizing
treatment for a hypertensive or diabetic patient, ADHD rating
scales can be similarly useful in the management of our patients.
The ADHD-Rating Scale (ADHD-RS), the Vanderbilt, and the
Conner’s are examples of ADHD scales that have been shown to be
consistent measures of core ADHD symptoms and are sensitive to
treatment effect.18–21 Various ratings of executive function such as
the Behavior Rating Inventory of Executive Function, can be
utilized to measure executive function deficits which frequently
cause impairment for ADHD individuals.22
Another group of scales has been developed to measure ADHD
symptoms and how they fluctuate throughout the day. Analog
Classroom and Analog Workplace settings have been developed
to measure ADHD symptoms and evaluate how long different
treatment modalities improve symptoms over the course of the
day. In these settings the 13 item SKAMP is used to measure
attention, behavior, and deportment in children and the Permanent Product Measure of Performance measures a child or adult’s
ability to sit and complete a series of basic math equations during
10 minutes and these tests are then repeated at various time points
throughout the day.16,23 The Before School Functioning Questionnaire (BSFQ) has been developed to help clinicians better evaluate
ADHD symptoms and functional impairments which cause significant disruption during the morning hours.24 The Parent Rating of
Evening and Morning Behavior (PREMB) evaluates behavioral
problems both in the morning (PREMB-AM) and evening
(PREMB-PM) in children.5
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Rating scales cannot only be used to detect breakthrough symptoms for pharmacotherapeutic adjustment but can also be used
to detect symptomatic or functional issues for psychotherapeutic
intervention. Family training, daily structure, and behavior modification can all be optimized by using appropriate rating scales to
monitor associated struggles throughout the day.

G.W. Mattingly and J. Young

Nearly half of these caregivers reported getting early to administer
ADHD medication before their child’s normal wake time to compensate for functional difficulties experienced before their child’s
medication was otherwise taking effect.32

Comorbid Conditions
Goals for Treatment
ADHD medications have some of the highest effect sizes of any
medical intervention.25 Studies also demonstrate, however, that
response to specific medications is highly individual. Studies show
that some patients respond equally well to either class, while other
individuals have a preferential response to either a methylphenidate preparation or an amphetamine preparation.26 Individuals
who have experienced adverse effects or have failed stimulants
may go on to either tolerate or preferentially respond to nonstimulant medications.27
Studies with all three classes of medications, methylphenidates,
amphetamines, and non-stimulants, have highlighted that it is all
too easy for clinicians to settle for partial improvement while still
leaving patients with ongoing symptomatology.28 Clinical response
has often been defined as a 25% to 30% symptom improvement, but
this still leaves patients with ongoing significant symptomatic and
functional impairment. Interestingly, clinicians interpret 30%
symptom improvement as “much” or even “very much improved”
on global clinical measures.29–32
Patients and clinicians may be tempted to be satisfied with 30%
improvement, even though the evidence is clear that such minimal
improvement almost inevitably means continued functional
impairment. For most patients, further improvement is possible.
Long-term trials demonstrate that nearly 75% to 80% of patients
can achieve >50% symptom reduction and achieve symptomatic
remission with overall Attention Deficit Hyperactivity Disorder
Raring Scale- ADHDRS scores of less than 18 (meaning that
ADHDRS scores are mild or less on average).33,34
Most individuals with ADHD will have moderate to moderately
severe symptoms when first presenting for diagnosis or treatment
with corresponding ADHD-RS scores in the 30 seconds to low 40
seconds (18 symptoms rated 0 to 3, 0 none, 1 mild, 2 moderate, and
3 severe).28
A recent study with MPH DR/ER dosed in the evening for
ADHD children demonstrated that ADHD symptoms could be
decreased from 42 to 11 after 6 weeks of dose titration, with an
average final dose of 60 mg per day. To put this in clinical perspective; these children were highly symptomatic with ADHD scores
that were moderate or severe on all 18 items and by the end of 6
weeks their ADHD symptoms were mild or none on average. This
and other studies point to the importance of appropriate titration
to optimize outcomes in our patients with ADHD28 (Figure 1).
In addition to overall symptom improvement, our treatments
must deliver symptomatic improvement at time points where
functional impairment is occurring for our patients. Studies by
Sallee, Whalen, Mattingly, and others have shown that clinicians
primarily focus on consequences of ADHD during school and work
while overlooking impairments that occur at the beginning and end
of the day.35–37 Sallee et al found that 79% of ADHD caregivers
have discussed early morning functional impairments such as
getting out of bed, getting dressed, self-hygiene, eating breakfast,
packing their backpack, and being able to catch the bus as being
some of the most impairing issues for their children with ADHD.

As now noted in DSM 5, ADHD frequently presents with a
constellation of associated emotional, behavioral, and cognitive
challenges.10 Young children with ADHD frequently have associated learning disorders or developmental disabilities such as difficulties with sensory integration, problems with working memory,
speech, and language delay, and difficulties with reading comprehension. A baseline battery of neurocognitive testing to detect
specific learning challenges should be considered in all schoolage children with ADHD. Recognition of specific learning challenges can help to better identify therapeutic interventions and
academic accommodations which can be of great benefit for children struggling with ADHD and associated learning difficulties.

Emotional Impulsivity, Oppositional Behavior, and Poor
Frustration Tolerance
Many children, adolescents, and adults with ADHD struggle with
symptoms associated with poor frustration tolerance. These symptoms can present in childhood as difficulty waiting, impatience with
delays, or excessive frustration when asked to shift from a preferred to
a nonpreferred task.36 Such frustration often leads to a sequence of
escalating emotional and behavioral dyscontrol, “meltdowns” out of
proportion to the task at hand, and emotional fragmentation.37,38
Oppositional thoughts and behaviors can trouble ADHD individuals of any age.39–41 Difficulties shifting from preferred to nonpreferred tasks and impaired recognition of the emotional impact
of their behavior on others frequently lead to such oppositional
patterns in ADHD individuals.
Appropriate medication selection can improve not just core
ADHD symptoms but can also improve morning function, morning behavioral issues, and evening behavior.38,42 The BSFQ allows
clinicians to monitor functional issues that a parent or caregiver are
noting to be disruptive for a child or their family in the morning
before school. The PREMB allows a clinician to disruptive behaviors in both the morning or evening. Morning behaviors include
getting up in the morning, getting ready for school, arguing with
siblings, or being late for school or the bus. Evening behaviors
include doing homework, eating dinner with the family, getting
ready for bed, and falling asleep (Tables 1 and 2; Figure 2).

Immediate-Release, Extended-Release, Delayed-Release, or
Combinations; Choosing Between Medication Options
The last several years have seen an explosion in stimulant delivery
systems available for ADHD treatment. Stimulants are now considered the first-line pharmacologic treatment option for individuals with ADHD.85,86 ADHD treatment has progressed from a
decision between short-acting methylphenidate (Ritalin, Methylin…) versus short-acting amphetamine (Dexedrine, Adderall…),
each of which required dosing several times per day in order to
maintain therapeutic efficacy.
Various strategies have been developed by pharmaceutical manufacturers to avoid the mid-day and intraday dosing. Early
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Figure 1. Optimizing symptom reduction results after 6 weeks of treatment.

modifications involved slow-release wax matrix technologies
(Ritalin SR…) that while extending the duration of action continued to have difficulties with variable release patterns from day to
day and from patient to patient depending on pH-related factors,
gastric motility, and meal effects.
The next set of sustained-release medications involved beaded
technologies (Adderall XR, Focalin XR…) where a certain percentage of medication was released in short-acting immediate release
beads while another percentage of beads were coated with a
pH-dependent layer that would begin releasing approximately 4
hours later in the less acidic small intestine providing clinical
efficacy for approximately 8 to 10 hours. These beaded technologies
allowed for adjustment of the percent immediate-release versus
sustained-release beads (30/70, 40/60, or 50/50) in order to have
greater delivery in the morning or increased medication delivery in
the afternoon. A triple bead mixed amphetamine salt compound
has been approved for adolescent and adults with ADHD. This
compound (Mydayis) was shown to achieve a 16 hour duration of
action in clinical trials.
A more recent adaptation of the beaded technology involves a
multi-layered release technology where each bead has an immediaterelease outer layer with an extended release inner layer. These
pH-dependent layers then dissolve as each bead passes through
various points in the intestinal tract. This multilayered release profile
results in a biphasic pharmacokinetic curve with an immediate first
peak 2 hours post dose and a second peak 8 hours post dose with an
MPH compound (Aptensio) achieving 12 hour duration of effect in
clinical trials. A longer duration multilayered MPH formulation
(Adhansia) has been approved with duration of improvement of
13 hours in pediatric trials and up to 16 hours in adult trials.

Beyond Beads
The OROS capsule (Concerta) provides a novel delivery system
with ongoing continuous release. After ingestion, stomach fluid is
absorbed through osmotic pores in one end of the capsule causing
medication to be excreted through a laser-drilled hole at the other
end of the capsule. The release occurs over 10 to 12 hours but many
patients experience a shorter duration of action.
A prodrug version of amphetamine was developed by binding
lysine to amphetamine. Lisdexamfetamine (Vyvanse) is a hydrophilic “biologically inactive” prodrug which is not able to cross the

bi-lipid blood–brain barrier. Lisdexamfetamine is enzymatically
cleaved into free amphetamine and free lysine by enzymes in the
cytosol of the human red blood cells providing sustained symptomatic improvement for 13 hours in children and 14 hours in
adults. Lisdexamfetamine can be dissolved in fluid such as juice
and administered in a liquid dose.

Transdermal
The ADHD field has one transdermal methylphenidate (Daytrana)
option which provides continuous transdermal release of methylphenidate from the moment the patch is applied with continued
efficacy until approximately 2 hours after the patch is removed.61,87
This allows flexibility of daytime dosing with shorter or longer wear
times depending on the individual needs of the patient. Unfortunately, adverse effects such as rash and skin discomfort often
hinder the use of this transdermal technology, although it should
be noted that a transdermal amphetamine based patch currently in
development may minimize some of the associated skin reactions.

Microparticles
A variety of pH based ion-exchange polymers have been developed
to allow ion exchange of stimulant molecules with underlying
microparticle polymers. These pH based microparticle polymer
technologies have allowed the development of sustained-release
orally disintegrating tablets (ODT). Sustained release
microparticle-based ODTs, MPH (Cotempla ODT) or amphetamine (Adzenys ODT) as well as a liquid suspension amphetamine
(Adzenys) are approved for treatment of ADHD. Each ODT has
stimulant molecules ionically bound to between 100 000 and 200 000
microparticles. A portion of these microparticles begin releasing
stimulant immediately when they encounter ions in gastric lumen
and some of these micorparticles are pH coated such that they will
not release stimulant until they have passed into the small intestine.
Another microparticle multilayered technology allows liquid
suspension or chewable tablets. Methylphenidate (Quillivant and
Quilichew) and amphetamine (Dyanavel) preparations are
approved for treatment of ADHD. These liquid formulations offer
sustained-release preparations that can be titrated in small increments for children that are especially sensitive to side effects.
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Delivery Mechanism and
Formulation

Generic Name

Brand
Name

Approved
Ages

Dosing
(Per Day)

Onset of
Effect

Duration of
Effect

108

Comments

References

Short-acting
Dexmethylphenidate
tablet

Dexmethylphenidate
HCL

Focalin

Children ≥6

2

NA

6h

Methylphenidate tablet

Methylphenidate HCL

Ritalin

Children ≥6,
adults

2 to 3

1 to 2 h

4h

Methylphenidate
chewable tablet and
liquid

Methylphenidate HCL

Methylin

Children ≥6,
adults

2 to 3

1 hb

4 hb

Methylphenidate tablet

Methamphetamine
HCL

Methylin ER

Children ≥6,
adults

1

NA

NA

Methylphenidate tablet

Methamphetamine
HCL

Ritalin-SR

Children ≥6,
adults

1

1.5 h

8h

Methylphenidate tablet

Methamphetamine
HCL

Metadate
ER

Children ≥6,
adults

1

NA

8h

Methylphenidate capsule

Methamphetamine
HCL

Metadate
CD

Children 6 to
15

1

1.5 h

8 to 9 h

Dexmethyl
phenidate capsule

Dexmethylphenidate
HCL

Focalin XR

Children ≥6,
adults

1

30 min

12 h

Methylphenidate
chewable tablet

Methylphenidate HCL

QuilliChew
ER

Children ≥6,
adults

1

45 min

8h

Methylphenidate
chewable tablet

Methylphenidate HCL

Ritalin LA

Children 6 to
12

1

30 min to
1h

12 h

Methylphenidate tablet

Methylphenidate HCL

Concerta

Children ≥6,
adults

1

1 to 2 h

Methylphenidate liquid

Methylphenidate HCL

Quillivant
XR

Children ≥6,
adults

1

45 min

12 h

Shake bottle vigorously for 10 s before dispensing

55, 58

Methylphenidate capsule

Methylphenidate HCL

Aptensio
XR

Children ≥6,
adults

1

1h

12 h

May be sprinkled

56, 59

Methylphenidate ODT

Methylphenidate

Cotempla
XR-ODT

Children ≥6

1

1h

12 h

No crushing or chewing Allow to disintegrate in saliva before
swallowing

56, 60

Methylphenidate
transdermal patch

Methylphenidate

Daytrana

Children ≥6

1

2h

12 h

Wear for ≤9 h

52, 61

Methylphenidate capsule

Methylphenidate HCL

Adhansia
XR

Children ≥6,
adults

1

1h

Methylphenidate capsule

Methylphenidate HCL

Jornay PM

Children ≥6,
adults

1

8 to 10 h

At least 4 h between doses

43, 44
45, 46

Chewable tablet: take with 8 oz of water 30 to 45 min before
meals
Oral solution: take 30 to 45 min before meals
Last dose before 6 PM

47, 48

Intermediate-acting
49
Take after meals for maximum duration of effect

43, 45
50

May be sprinkled on applesauce

51, 52

May be sprinkled

53, 54

Long-acting

55, 56
May be sprinkled

10 to 12 h

13 to 16 h
12+ h

43, 52, 56
52, 57

May be sprinkled and consumed within 10 min
Take in the evening between 6:30 and 9:30 PM for early morning
symptom control may be sprinkled

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available; ODT, orally disintegrating tablet.
a
The American Academy of Pediatrics recommends utilizing methylphenidate as the first choice for preschool-aged children.23
b
Methylin is bioequivalent to Ritalin,5 but it has not been tested independently in a classroom study.
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Table 2. FDA-Approved Amphetamine Formulations for ADHD
Onset
of
Effect

Duration
of Effect

Generic Name

Brand Name

Approved Ages

Dosing
(Per
Day)

Amphetamine tablet

Amphetamine mixed
salts

Adderall

Children ≥3

1 to 3

1.5 h

4 to 6 h

Dextroamphetamine
tablet

Dextroamphetamine
sulfate

Dexedrine

Children 3 to 16

1 to 2

NA

4 to 6 h

67, 69

Dextroamphetamine
tablet

Dextroamphetamine
sulfate

Zenzedi

Children 3 to 16

1 to 3

NA

4 to 6 h

70

Dextroamphetamine
liquid

Dextroamphetamine
sulfate

ProCentra

Children 6 to 16

1 to 2

NA

6 to 10 h

Methamphetamine
tablet

Methamphetamine
HCL

Desoxyn

Children ≥6

1 to 2

NA

NA

Amphetamine tablet
and ODT

Racemic
amphetamine
sulfate

Evekeo

Children ≥3 (tablet)
Children 6 to 17
(ODT)

1 to 2

45 min

9.25 h

Dextroamphetamine
capsule

Dextroamphetamine
sulfate

Dexedrine
spansule

Children 6 to 16

1 to 2

NA

6 to 10 h

Amphetamine capsule

Amphetamine mixed
salts

Adderall XR

Children ≥6, adults

1

1.5 h

10.5 to
12 h

Amphetamine liquid

Amphetamine

Adzenys ER

Children ≥6, adults

1

1.5 ha

10 to 12
ha

Do not add to food or other liquids

78

Amphetamine ODT

Amphetamine

Adzenys
XR-ODT

Children ≥6, adults

1

1.5 ha

10 to 12
ha

Allow tablet to disintegrate in saliva before swallowing

79

Amphetamine liquid

Amphetamine

Dyanavel XR

Children ≥6

1

1h

12

Amphetamine capsule

Amphetamine mixed
salts

Mydayis

Children ≥13, adults

1

2h

14 h

Amphetamine prodrug
capsule and
chewable tablet

Lisdexamfetamine
dimesylate

Vyvanse

Children ≥6, adults

1

1.5 to 2
h

12 to 14 h

Delivery Mechanism and
Formulation

Comments

References

Short-acting
Elimination half-life 9.77 to 11 h for the D-isomer and 11.5 to
13.8 h for L-isomer

65–68

Plasma half-life of approximately 12 h

71

Not readily available

72

Intermediate-acting
Elimination half-life 10.0 to 11.7 h

73–75

Plasma half-life of approximately 12 h

67, 69

May be sprinkled on applesauce

76, 77

Long-acting

80
May be sprinkled on applesauce

81, 82

Capsule: may be sprinkled in water, orange juice, or yogurt
Chewable tablet: chew thoroughly before swallowing

83, 84

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available; ODT, orally disintegrating tablet.
a
Adzenys XR-ODT and Adzenys ER are bioequivalent to extended-release mixed amphetamine salts (ie, Adderall XR),42, 85 but have not been tested independently in a classroom study.
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Figure 2. Improving function and behavior.

Nighttime Dosing

Adjusting Medication to Optimizing Outcomes

A unique microparticle MPH medication (Jornay PM) has been
developed to improve ADHD symptoms both in the morning upon
awakening yet also provide sustained duration to improve ADHD
symptoms throughout the day until bedtime. This delayed release
extended release “DR/ER” ADHD medication is designed to be
taken around 8 pm in the evening. The outer delayed release layer
does not allow the medication to begin absorption until 5 to 6 am.
The inner extended release layer provides gradual stimulant release
into the early evening. This technology demonstrated improvement in morning behavior, before school functioning, reduction in
core ADHD symptoms, and improvement in evening behavior.

Quite often a patient will return stating that “I’m doing better” after
starting an ADHD treatment. The question is are they normalized,
are they partially better but still symptomatic, are their symptoms still
causing functional difficulties at various points throughout the day or
in certain areas of their life. Are they partially better but not well?
Studies around the world have demonstrated the need to gradually adjust the dose and titrate for optimal effect. Many consumer
databases have shown that quite often ADHD medications are
being prescribed at doses below what was shown to be the optimal
effective dose. The rule of thumb is to titrate until there are no
breakthrough symptoms or residual functional difficulties or one
encounters a dose-limiting side effect or has reached the maximum
dose. One should then consider trying an alternative moleculeMPH, amphetamine, or nonstimulant or an alternative formulation of the same molecule that may address breakthrough symptoms at the beginning, the middle, or the end of the day.

Nonstimulants
Three noradrenergic non-stimulants are currently approved in the
United States for treatment of ADHD. The options either block
reuptake of norepinephrine transporters (atomoxetine, Strattera)
or directly stimulate the norepinephrine alpha 2a receptor
(guanfacine-XR, Intuniv, and clonidine-XR, Kapvay). These
options may be utilized for individuals who cannot tolerate the
dopaminergic side effects of stimulants, require 24 hour symptomatic coverage or who have significant concerns about abuse or
diversion of stimulants. In addition, both guanfacine-XR and
clonidine-XR are approved for use in combination with a stimulant
for children who have break through symptoms on a stimulant
alone.
A fourth novel nonstimulant (viloxazine XR) is set for tentative
approval by the FDA in early 2021. Viloxazine, considered a
“multimodal agent” in that it both blocks the norepinephrine
reuptake pump and directly modulates several serotonin receptors
with elevation of intrasynaptic serotonin levels. Viloxazine will
likely initially be approved for children and adolescents with positive adult ADHD studies reported in December 2020 (Table 3).

Breakthrough Symptoms
End of the day breakthrough symptoms one should consider:
(1) Increase dose of current medication to see if it will provide
longer coverage.
(2) Change to a formulation with a longer durationa. short acting to intermediate-MPH to MPH XR, AMPH
to AMPH XR
b. intermediate to long-MPH XR to OROS MPH, AMPH
XR to Lisdexamphetamine
c. long to longer-OROS MPH to MPH XXR or MPH
DR/ER, Lisdexamphetamine to AMPH XXR
(3) Consider adding a nonstimulant-atomoxetine, guanfacine,
clonidine, viloxazine.
(4) Consider using a long-acting stimulant and adding a shortacting stimulant at the end of the day.
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(5) Consider layering 2 doses of long-acting stimulant-one in the
morning and one around noon.

24 h
1 wk
1
Children 6 to
17
SPN-812c

Guanfacine

Viloxazine
HCL

Alpha2-adrenergic receptor agonist
tablet

Serotonin norepinephrine modulating
agent capsule

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; FDA, U.S. Food and Drug Administration; HCL, hydrochloride; NA, not available.
a
Time to onset of the full effect of nonstimulant medications is extended compared to stimulant medications due to long titration periods.43, 86, 97
b
The duration of effect of atomoxetine has not been formally measured as in studies of stimulation medications. Evidence from clinical studies suggests that one-daily dosing of atomoxetine is associated with efficacy into the evening.48
c
Pending FDA approval.49

94–96

92, 93
An antihypertensive agent may be prescribed in
addition to a stimulant
Dosed by body weight
Up to 24 h per
dose
1
Children ≥6
Intuniv

3 wk

90, 91
An antihypertensive agent may be prescribed in
addition to a stimulant
Discontinuation must be gradual
NA
2 wk
2
Children ≥6
Clonidine
HCL
Alpha2-adrenergic receptor agonist
tablet

Kapvay

1 to 2
Children ≥6,
adults
Atomoxetine
Norepinephrine transporter reuptake
inhibitor capsule

Long-acting

Delivery Mechanism and Formulation

Generic
Name

Table 3. FDA-Approved Nonstimulant Medications for ADHD

Brand
Name

Strattera

Approved
Ages

Dosing
(Per
Day)

3 to 4 wk

Onset of Effecta

NAb

Duration of
Effect

Comments

Dosed by body weight

88, 89

References

111

Beginning of the day breakthrough symptoms one should consider:
(1) Give the morning dose as early as possible.
(2) Adding a bit of short-acting stimulant in the morning with the
long-acting stimulant.
(3) Using a long-acting stimulant that releases more medication in
the IR component.
(4) Adding a nonstimulant with 24 hour coverage-atomoxetine,
viloxazine.
(5) Switching to 8 pm dosing of MPH DR/ER to allow blood level
ascendency to coincide with morning awakening.
Summary
Our knowledge and understanding of the underlying neurobiology
and symptomatic expression of ADHD has advanced dramatically
over the past decade. Associated with these advances has been a
similar explosion of new formulations for individualization of
treatment based on our patient’s needs. Optimized treatment is
enhanced by measuring and tracking ADHD symptoms with the
goal of treating to symptomatic remission with minimal functional
impairment. Individual clinical presentation and patient response
guide a clinician’s choice between chemical classes of medications:
methylphenidate, amphetamine, or non-stimulant. Within both
classes of stimulant, we now have delivery systems that tailor the
release kinetics to each individual patient with immediate-release,
8-hour sustained-release, 12 hour sustained-release, and 13 to 16
hour sustained-release. In addition, we now have an evening dosed
DR/ER methylphenidate that captures morning symptoms with
sustained symptom control throughout the day and into the evening. A deeper understanding of the functional difficulties encountered by ADHD patients throughout their lives, coupled with more
consistent use of ADHD rating scales enables clinicians to choose
between a wide variety of medication delivery systems in order to
optimize the outcome for each of their patients.98–103
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Optional Posttest and CME Certificate
CME Credit Expires: December 18, 2023

Posttest Study Guide
The posttest can only be submitted online. The below posttest questions have been provided solely as a study tool to prepare for your
online submission. Faxed/mailed copies of the posttest cannot be processed and will be returned to the sender. If you do not have access
to a computer, contact NEI customer service at 888-535-5600.
1. Kim is a 9-year-old patient with ADHD who is having breakthrough symtoms early in the day with guanfacine. Which of the following
treatment changes would be most appropriate to improve her symptoms?
A. Increase the dose of guanfacine
B. Change to a formulation with longer duration
C. Use a long-acting stimulant that releases more medication in the immediate release component
D. None of these changes are appropriate
2. Jenny is a 15-year-old patient who was recently diagnosed with ADHD. In addition to early morning tennis practice, Jenny participates
in several after-school activities that keep her busy into the late afternoon, after which she begins her homework. Which of the following
treatments is most appropriate for a patient like Jenny who needs all-day symptom relief?
A. Jornay PM
B. Ritalin
C. Adderall
D. Dexedrine
3. Samson is a 24-year-old patient with comorbid ADHD and sustance use disorder. He wants to avoid ADHD medication that has abuse
potential. Which of the following treatments may be most appropriate for Samson?
A. Viloxazine
B. Atomoxetine
C. Methylphenidate
D. None of these treatments are appropropriate
Instructions for Optional Online Posttest and CME Certificate
1. Read the article
2. Complete the posttest, available only online at www.neiglobal.com/CME (under “CNS Spectrums”)
3. Print your certificate (passing score=70% or higher)
Questions? call 888-535-5600, or email CustomerService@neiglobal.com
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